A new method using CRISPR to restore retinal function in mice with the degenerative retinal disease Retinitis Pigmentosa Pipeline Drugs Market has been developed by Columbia University in the United States.

CRISPR technology has never before been successfully applied to a dominant disorder, an inherited condition. Huntington's disease, Marfan syndrome, and corneal dystrophies are just a few of the hundreds of human diseases that could be treated using this method.

The goal of Dr. Stephen Tsang and his coworkers was to develop a more adaptable CRISPR tool that could treat a greater number of patients, regardless of their unique genetic profiles. Because it removes the undesirable gene and replaces it with a gene that works, Tsang refers to the method as genome surgery. In three years, human trials are expected to begin.

into the Retinitis Pigmentosa pipeline drugs market, download a free report sample

Tsang stated: Surgery on the genome is coming. Before the rest of medicine, genome surgery will be performed first in ophthalmology.

One of more than 70 genes is responsible for the rare genetic disorders known as retinitis pigmentosa. Cells in the retina die and break down as a result. It typically begins in childhood and progresses slowly, affecting night vision and peripheral vision. The majority of people who have this condition will lose a lot of their sight by early adulthood, and they will be legally blind by the time they are 40. It is estimated to affect one in 4,000 people worldwide and there is no cure.